| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Retroviridae Infections | 15 | 2019 | 45 | 6.69 | Why? |
| Friend murine leukemia virus | 17 | 2019 | 29 | 5.53 | Why? |
| Tumor Virus Infections | 6 | 2019 | 127 | 1.40 | Why? |
| Killer Cells, Natural | 4 | 2018 | 2093 | 1.07 | Why? |
| T-Lymphocytes, Regulatory | 3 | 2018 | 698 | 1.02 | Why? |
| Cytotoxicity, Immunologic | 5 | 2021 | 287 | 1.00 | Why? |
| Retroviridae | 3 | 2018 | 49 | 0.94 | Why? |
| Neoplasms, Experimental | 2 | 2019 | 67 | 0.92 | Why? |
| CD8-Positive T-Lymphocytes | 17 | 2020 | 5837 | 0.84 | Why? |
| Interferon-alpha | 6 | 2019 | 1442 | 0.82 | Why? |
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2019 | 41 | 0.78 | Why? |
| Immunity, Cellular | 8 | 2021 | 3614 | 0.78 | Why? |
| Simian Acquired Immunodeficiency Syndrome | 2 | 2018 | 154 | 0.77 | Why? |
| Leukemia, Experimental | 2 | 2017 | 3 | 0.77 | Why? |
| Natural Killer T-Cells | 2 | 2021 | 191 | 0.76 | Why? |
| Immunologic Surveillance | 1 | 2019 | 69 | 0.74 | Why? |
| Simian Immunodeficiency Virus | 2 | 2018 | 251 | 0.72 | Why? |
| Fas Ligand Protein | 1 | 2017 | 69 | 0.69 | Why? |
| Hepatitis B virus | 6 | 2019 | 882 | 0.62 | Why? |
| CD4-Positive T-Lymphocytes | 6 | 2020 | 4545 | 0.55 | Why? |
| Mice | 25 | 2019 | 21357 | 0.52 | Why? |
| Lymphocyte Activation | 6 | 2020 | 2742 | 0.52 | Why? |
| Mice, Inbred C57BL | 16 | 2019 | 5542 | 0.52 | Why? |
| Models, Immunological | 1 | 2018 | 727 | 0.48 | Why? |
| HIV-1 | 7 | 2019 | 3365 | 0.47 | Why? |
| Interleukin-10 | 1 | 2018 | 1409 | 0.44 | Why? |
| Immunologic Memory | 2 | 2020 | 3362 | 0.40 | Why? |
| Animals | 41 | 2021 | 78931 | 0.39 | Why? |
| BK Virus | 3 | 2019 | 135 | 0.38 | Why? |
| Pancreas Transplantation | 2 | 2020 | 163 | 0.37 | Why? |
| Adaptive Immunity | 1 | 2019 | 2585 | 0.34 | Why? |
| Toll-Like Receptor 2 | 2 | 2019 | 198 | 0.34 | Why? |
| Hepatitis B, Chronic | 3 | 2019 | 616 | 0.33 | Why? |
| T-Lymphocytes | 7 | 2020 | 6670 | 0.32 | Why? |
| Hepatitis B | 4 | 2018 | 888 | 0.30 | Why? |
| HIV Infections | 8 | 2019 | 11620 | 0.29 | Why? |
| Antigens, CD | 3 | 2020 | 984 | 0.29 | Why? |
| Membrane Glycoproteins | 4 | 2020 | 2273 | 0.28 | Why? |
| Mice, Knockout | 9 | 2019 | 1815 | 0.27 | Why? |
| Kidney Transplantation | 6 | 2021 | 5397 | 0.26 | Why? |
| Adoptive Transfer | 3 | 2018 | 250 | 0.25 | Why? |
| Oligonucleotides | 1 | 2003 | 137 | 0.25 | Why? |
| Polyomavirus Infections | 3 | 2019 | 156 | 0.24 | Why? |
| CpG Islands | 1 | 2003 | 230 | 0.24 | Why? |
| Calcium Phosphates | 2 | 2018 | 35 | 0.24 | Why? |
| Dendritic Cells | 4 | 2019 | 1330 | 0.24 | Why? |
| Disease Models, Animal | 6 | 2018 | 10998 | 0.22 | Why? |
| Host-Pathogen Interactions | 4 | 2019 | 11041 | 0.22 | Why? |
| Virus Inactivation | 2 | 2021 | 1139 | 0.22 | Why? |
| Immunity, Innate | 1 | 2019 | 6570 | 0.22 | Why? |
| Receptor, Interferon alpha-beta | 3 | 2018 | 610 | 0.21 | Why? |
| Receptors, Peptide | 1 | 2020 | 32 | 0.21 | Why? |
| Mice, Transgenic | 5 | 2019 | 2739 | 0.21 | Why? |
| Immunotherapy | 3 | 2019 | 2421 | 0.21 | Why? |
| Semaphorins | 1 | 2019 | 12 | 0.20 | Why? |
| Interleukin-15 | 2 | 2017 | 169 | 0.20 | Why? |
| Pasteurization | 1 | 2020 | 102 | 0.20 | Why? |
| Immunoglobulin G | 8 | 2021 | 21571 | 0.20 | Why? |
| Receptors, OX40 | 1 | 2019 | 6 | 0.20 | Why? |
| Antibodies, Viral | 15 | 2021 | 51949 | 0.20 | Why? |
| Membrane Proteins | 2 | 2021 | 1733 | 0.20 | Why? |
| Monitoring, Immunologic | 1 | 2020 | 153 | 0.20 | Why? |
| Herpesvirus Vaccines | 1 | 2018 | 9 | 0.20 | Why? |
| Regulatory Sequences, Nucleic Acid | 1 | 2019 | 95 | 0.19 | Why? |
| Matrix Metalloproteinase 2 | 1 | 2019 | 85 | 0.19 | Why? |
| TOR Serine-Threonine Kinases | 2 | 2019 | 385 | 0.19 | Why? |
| Disinfection | 3 | 2021 | 2912 | 0.19 | Why? |
| Hepatitis B Antigens | 1 | 2018 | 19 | 0.19 | Why? |
| Viral Envelope Proteins | 3 | 2017 | 3539 | 0.19 | Why? |
| Lymphocytic Choriomeningitis | 1 | 2018 | 43 | 0.19 | Why? |
| Lymphopoiesis | 1 | 2018 | 26 | 0.19 | Why? |
| Glycyrrhizic Acid | 1 | 2021 | 190 | 0.19 | Why? |
| Transplantation, Homologous | 2 | 2020 | 757 | 0.18 | Why? |
| Glycolysis | 1 | 2019 | 208 | 0.18 | Why? |
| Erythroblasts | 1 | 2017 | 19 | 0.18 | Why? |
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2017 | 15 | 0.18 | Why? |
| Lymphocytic choriomeningitis virus | 1 | 2018 | 98 | 0.18 | Why? |
| Matrix Metalloproteinase 9 | 1 | 2019 | 211 | 0.18 | Why? |
| Lymphoid Tissue | 1 | 2018 | 162 | 0.18 | Why? |
| Antiviral Agents | 12 | 2021 | 41703 | 0.17 | Why? |
| Meningoencephalitis | 1 | 2020 | 208 | 0.17 | Why? |
| Cardiomyopathy, Dilated | 1 | 2020 | 251 | 0.17 | Why? |
| Immunity, Humoral | 3 | 2021 | 4849 | 0.17 | Why? |
| Toll-Like Receptors | 2 | 2018 | 365 | 0.17 | Why? |
| Retinitis | 1 | 2017 | 42 | 0.17 | Why? |
| Carcinoembryonic Antigen | 1 | 2018 | 140 | 0.17 | Why? |
| RNA, Untranslated | 1 | 2018 | 140 | 0.17 | Why? |
| ADAMTS13 Protein | 1 | 2021 | 363 | 0.17 | Why? |
| Cell Proliferation | 3 | 2019 | 1973 | 0.16 | Why? |
| Acyclovir | 1 | 2017 | 154 | 0.16 | Why? |
| Virus Replication | 7 | 2021 | 14331 | 0.16 | Why? |
| Cytokines | 8 | 2021 | 15010 | 0.16 | Why? |
| Herpesviridae | 1 | 2017 | 100 | 0.16 | Why? |
| Antibodies, Neutralizing | 7 | 2021 | 25288 | 0.16 | Why? |
| Transgenes | 1 | 2017 | 227 | 0.16 | Why? |
| Purpura, Thrombotic Thrombocytopenic | 1 | 2021 | 284 | 0.16 | Why? |
| Genetic Predisposition to Disease | 2 | 2021 | 4027 | 0.16 | Why? |
| Granulocytes | 1 | 2017 | 140 | 0.16 | Why? |
| Nanoparticles | 2 | 2018 | 2040 | 0.16 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 552 | 0.16 | Why? |
| Nuclear Medicine | 2 | 2020 | 585 | 0.16 | Why? |
| Lymphocyte Subsets | 2 | 2020 | 987 | 0.15 | Why? |
| Receptors, Interleukin-1 | 1 | 2017 | 161 | 0.15 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2017 | 593 | 0.15 | Why? |
| Anti-Retroviral Agents | 3 | 2019 | 1099 | 0.15 | Why? |
| Antibody Specificity | 1 | 2020 | 1328 | 0.15 | Why? |
| Herpesvirus 1, Human | 1 | 2018 | 286 | 0.15 | Why? |
| Toll-Like Receptor 7 | 1 | 2019 | 402 | 0.15 | Why? |
| Cells, Cultured | 5 | 2019 | 5835 | 0.15 | Why? |
| Convalescence | 3 | 2021 | 2829 | 0.15 | Why? |
| Interleukin-18 | 1 | 2017 | 328 | 0.15 | Why? |
| Transcription, Genetic | 2 | 2019 | 1326 | 0.15 | Why? |
| Cell Adhesion Molecules | 1 | 2018 | 472 | 0.14 | Why? |
| Tumor Microenvironment | 1 | 2017 | 264 | 0.14 | Why? |
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 291 | 0.14 | Why? |
| Germany | 9 | 2021 | 9196 | 0.14 | Why? |
| von Willebrand Factor | 1 | 2021 | 668 | 0.14 | Why? |
| env Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 386 | 0.14 | Why? |
| Radiotherapy | 1 | 2020 | 608 | 0.14 | Why? |
| Hepatocytes | 1 | 2018 | 549 | 0.14 | Why? |
| Monomeric GTP-Binding Proteins | 1 | 2013 | 12 | 0.14 | Why? |
| Colitis | 1 | 2017 | 266 | 0.14 | Why? |
| Ultraviolet Rays | 2 | 2021 | 1272 | 0.13 | Why? |
| Th2 Cells | 1 | 2018 | 680 | 0.13 | Why? |
| Female | 37 | 2021 | 380317 | 0.13 | Why? |
| Vaccines, DNA | 2 | 2017 | 871 | 0.13 | Why? |
| HIV Envelope Protein gp120 | 1 | 2016 | 267 | 0.13 | Why? |
| Myeloid-Derived Suppressor Cells | 1 | 2017 | 316 | 0.13 | Why? |
| Immune System | 1 | 2003 | 1479 | 0.13 | Why? |
| RNA-Binding Proteins | 1 | 2021 | 1022 | 0.13 | Why? |
| Humans | 65 | 2021 | 930598 | 0.13 | Why? |
| Immunotherapy, Adoptive | 1 | 2018 | 524 | 0.12 | Why? |
| Immune Tolerance | 1 | 2018 | 608 | 0.12 | Why? |
| RNA, Viral | 6 | 2021 | 32276 | 0.12 | Why? |
| Virus Activation | 1 | 2017 | 480 | 0.12 | Why? |
| Cell Line, Tumor | 2 | 2019 | 3608 | 0.12 | Why? |
| Immunodominant Epitopes | 1 | 2017 | 813 | 0.12 | Why? |
| Cytomegalovirus | 1 | 2017 | 600 | 0.12 | Why? |
| Heart-Assist Devices | 1 | 2020 | 812 | 0.12 | Why? |
| Milk, Human | 1 | 2020 | 956 | 0.11 | Why? |
| Adenoviridae | 1 | 2017 | 1151 | 0.11 | Why? |
| Phenotype | 2 | 2021 | 4037 | 0.11 | Why? |
| Apoptosis | 2 | 2021 | 2335 | 0.11 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.11 | Why? |
| Cytomegalovirus Infections | 1 | 2017 | 667 | 0.11 | Why? |
| Point-of-Care Testing | 2 | 2021 | 2782 | 0.11 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2021 | 3607 | 0.11 | Why? |
| Protein Array Analysis | 1 | 2013 | 387 | 0.11 | Why? |
| Monocytes | 2 | 2020 | 2978 | 0.11 | Why? |
| Mice, Inbred BALB C | 5 | 2019 | 5814 | 0.10 | Why? |
| Blood Donors | 2 | 2021 | 2956 | 0.10 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.10 | Why? |
| Immunization, Passive | 3 | 2021 | 10067 | 0.10 | Why? |
| Receptors, Virus | 2 | 2020 | 5659 | 0.10 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2017 | 830 | 0.10 | Why? |
| Leukocyte Count | 1 | 2020 | 3178 | 0.10 | Why? |
| Anti-HIV Agents | 2 | 2019 | 2209 | 0.10 | Why? |
| Enzyme-Linked Immunospot Assay | 2 | 2021 | 325 | 0.10 | Why? |
| Chronic Disease | 3 | 2019 | 5139 | 0.10 | Why? |
| Immunoglobulin M | 3 | 2021 | 9091 | 0.10 | Why? |
| Male | 30 | 2021 | 367725 | 0.09 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.09 | Why? |
| Immunocompromised Host | 3 | 2020 | 5150 | 0.09 | Why? |
| T-Lymphocyte Subsets | 3 | 2021 | 1387 | 0.09 | Why? |
| Coronavirus Infections | 16 | 2020 | 253789 | 0.09 | Why? |
| Lung Transplantation | 1 | 2020 | 1554 | 0.09 | Why? |
| Communicable Diseases | 1 | 2003 | 2148 | 0.09 | Why? |
| HEK293 Cells | 5 | 2019 | 8394 | 0.09 | Why? |
| Macrophages | 2 | 2017 | 2784 | 0.09 | Why? |
| Gene Knockout Techniques | 2 | 2019 | 347 | 0.09 | Why? |
| Macaca mulatta | 1 | 2018 | 3716 | 0.09 | Why? |
| Liver | 2 | 2019 | 4007 | 0.08 | Why? |
| Middle Aged | 24 | 2021 | 270681 | 0.08 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.08 | Why? |
| Complement System Proteins | 1 | 2010 | 380 | 0.08 | Why? |
| Coronavirus | 5 | 2013 | 18339 | 0.08 | Why? |
| Vero Cells | 5 | 2021 | 14117 | 0.08 | Why? |
| Caco-2 Cells | 2 | 2020 | 1236 | 0.08 | Why? |
| Kidney Diseases | 1 | 2018 | 1434 | 0.08 | Why? |
| Melanoma | 1 | 2017 | 1229 | 0.08 | Why? |
| Aged | 20 | 2021 | 215776 | 0.08 | Why? |
| Flow Cytometry | 3 | 2020 | 2393 | 0.08 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2017 | 2262 | 0.08 | Why? |
| Viral Vaccines | 2 | 2018 | 7560 | 0.08 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.07 | Why? |
| Interleukin-2 | 2 | 2017 | 443 | 0.07 | Why? |
| Peptide Fragments | 1 | 2016 | 2075 | 0.07 | Why? |
| Pneumonia, Viral | 10 | 2020 | 243684 | 0.07 | Why? |
| Interferon Type I | 1 | 2018 | 2789 | 0.07 | Why? |
| Protease Inhibitors | 1 | 2021 | 3630 | 0.07 | Why? |
| Cell Survival | 2 | 2021 | 1581 | 0.07 | Why? |
| Adult | 19 | 2021 | 244371 | 0.07 | Why? |
| Molecular Diagnostic Techniques | 1 | 2021 | 4239 | 0.07 | Why? |
| Immunologic Factors | 2 | 2019 | 4206 | 0.07 | Why? |
| Receptors, Antigen, T-Cell | 2 | 2020 | 760 | 0.07 | Why? |
| Skin Neoplasms | 1 | 2017 | 1679 | 0.07 | Why? |
| Renal Dialysis | 1 | 2021 | 4358 | 0.07 | Why? |
| Spleen | 2 | 2018 | 877 | 0.06 | Why? |
| Genotype | 3 | 2021 | 4697 | 0.06 | Why? |
| Gene Expression Profiling | 3 | 2020 | 3788 | 0.06 | Why? |
| Transplant Recipients | 4 | 2021 | 4982 | 0.06 | Why? |
| DNA, Viral | 3 | 2018 | 2521 | 0.06 | Why? |
| Lymphocyte Count | 3 | 2020 | 4758 | 0.06 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.06 | Why? |
| Immunosuppressive Agents | 2 | 2018 | 6331 | 0.06 | Why? |
| Cell Differentiation | 2 | 2020 | 1338 | 0.06 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.06 | Why? |
| Nervous System Diseases | 1 | 2020 | 4092 | 0.06 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.06 | Why? |
| Postoperative Complications | 1 | 2020 | 5861 | 0.06 | Why? |
| Antigens, Viral | 1 | 2018 | 6298 | 0.05 | Why? |
| Cytotoxins | 1 | 2020 | 57 | 0.05 | Why? |
| Spike Glycoprotein, Coronavirus | 6 | 2021 | 37182 | 0.05 | Why? |
| Transplantation Immunology | 1 | 2021 | 99 | 0.05 | Why? |
| Plant Roots | 1 | 2021 | 108 | 0.05 | Why? |
| Soaps | 1 | 2021 | 134 | 0.05 | Why? |
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 30 | 0.05 | Why? |
| Phosphoproteins | 2 | 2021 | 4346 | 0.05 | Why? |
| Genetic Vectors | 2 | 2017 | 1600 | 0.05 | Why? |
| Glycyrrhiza | 1 | 2021 | 141 | 0.05 | Why? |
| Cosmetics | 1 | 2021 | 100 | 0.05 | Why? |
| Immunity | 1 | 2011 | 2651 | 0.05 | Why? |
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2018 | 3 | 0.05 | Why? |
| Cyclosporins | 1 | 2018 | 16 | 0.05 | Why? |
| Luminescent Proteins | 1 | 2019 | 142 | 0.05 | Why? |
| Cerebrospinal Fluid | 1 | 2020 | 234 | 0.05 | Why? |
| Diagnostic Tests, Routine | 2 | 2021 | 2643 | 0.05 | Why? |
| Interferon-gamma | 2 | 2020 | 2711 | 0.05 | Why? |
| Animal Use Alternatives | 1 | 2018 | 6 | 0.05 | Why? |
| Interferon Regulatory Factors | 1 | 2019 | 141 | 0.05 | Why? |
| Intravital Microscopy | 1 | 2018 | 34 | 0.05 | Why? |
| Chimera | 1 | 2018 | 83 | 0.05 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.05 | Why? |
| Protein Isoforms | 1 | 2019 | 347 | 0.05 | Why? |
| Prosthesis Implantation | 1 | 2020 | 261 | 0.04 | Why? |
| Immunomodulation | 2 | 2017 | 1472 | 0.04 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.04 | Why? |
| Gene Products, gag | 1 | 2017 | 28 | 0.04 | Why? |
| Immunization | 2 | 2017 | 2019 | 0.04 | Why? |
| Lymphopenia | 2 | 2020 | 2669 | 0.04 | Why? |
| Cross-Over Studies | 1 | 2021 | 867 | 0.04 | Why? |
| Antibody Formation | 2 | 2021 | 4038 | 0.04 | Why? |
| Cell Count | 1 | 2017 | 228 | 0.04 | Why? |
| Enterotoxins | 1 | 2017 | 115 | 0.04 | Why? |
| Ganciclovir | 1 | 2017 | 97 | 0.04 | Why? |
| Signal Transduction | 3 | 2019 | 7207 | 0.04 | Why? |
| Myeloid Differentiation Factor 88 | 1 | 2017 | 109 | 0.04 | Why? |
| Interleukin-1 Receptor-Associated Kinases | 1 | 2017 | 56 | 0.04 | Why? |
| Quality Control | 1 | 2021 | 628 | 0.04 | Why? |
| Pandemics | 13 | 2020 | 389249 | 0.04 | Why? |
| Lipopeptides | 1 | 2019 | 229 | 0.04 | Why? |
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 372 | 0.04 | Why? |
| Hospitals, University | 2 | 2021 | 4173 | 0.04 | Why? |
| Probability | 1 | 2020 | 923 | 0.04 | Why? |
| Sirolimus | 1 | 2018 | 240 | 0.04 | Why? |
| Enzyme Activation | 1 | 2017 | 425 | 0.04 | Why? |
| Viral Load | 4 | 2020 | 15850 | 0.04 | Why? |
| Adenovirus Vaccines | 1 | 2017 | 103 | 0.04 | Why? |
| Encephalitis, Viral | 1 | 2020 | 355 | 0.04 | Why? |
| Gene Editing | 1 | 2019 | 330 | 0.04 | Why? |
| CTLA-4 Antigen | 1 | 2017 | 282 | 0.04 | Why? |
| Cell Separation | 1 | 2018 | 270 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Genome, Viral | 2 | 2020 | 13157 | 0.04 | Why? |
| Antigens, Differentiation | 1 | 2017 | 172 | 0.04 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.04 | Why? |
| Virus Latency | 1 | 2018 | 251 | 0.04 | Why? |
| HIV-2 | 1 | 2016 | 92 | 0.04 | Why? |
| Neutralization Tests | 2 | 2020 | 6698 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2018 | 647 | 0.04 | Why? |
| B-Lymphocytes | 1 | 2010 | 4418 | 0.04 | Why? |
| Austria | 1 | 2020 | 1259 | 0.04 | Why? |
| Blotting, Western | 1 | 2018 | 863 | 0.04 | Why? |
| Tacrolimus | 1 | 2018 | 435 | 0.04 | Why? |
| Bone Marrow Transplantation | 1 | 2018 | 343 | 0.04 | Why? |
| Hepatitis B Vaccines | 1 | 2017 | 245 | 0.04 | Why? |
| HIV Envelope Protein gp41 | 1 | 2016 | 153 | 0.04 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.03 | Why? |
| Nitriles | 1 | 2019 | 1053 | 0.03 | Why? |
| Cell Membrane | 1 | 2019 | 743 | 0.03 | Why? |
| Deoxyribonucleotides | 1 | 2013 | 3 | 0.03 | Why? |
| Random Allocation | 1 | 2017 | 773 | 0.03 | Why? |
| SAM Domain and HD Domain-Containing Protein 1 | 1 | 2013 | 20 | 0.03 | Why? |
| False Negative Reactions | 1 | 2021 | 1785 | 0.03 | Why? |
| Plasma Exchange | 1 | 2021 | 763 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2021 | 9537 | 0.03 | Why? |
| Virus Internalization | 1 | 2013 | 7921 | 0.03 | Why? |
| Imidazoles | 1 | 2019 | 631 | 0.03 | Why? |
| Analysis of Variance | 1 | 2017 | 950 | 0.03 | Why? |
| Statistics, Nonparametric | 1 | 2017 | 1008 | 0.03 | Why? |
| Plasmids | 1 | 2017 | 840 | 0.03 | Why? |
| Drug Synergism | 1 | 2017 | 833 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.03 | Why? |
| Leukocytes | 1 | 2020 | 1046 | 0.03 | Why? |
| Endosomes | 1 | 2017 | 490 | 0.03 | Why? |
| Hot Temperature | 1 | 2021 | 1299 | 0.03 | Why? |
| Cell Culture Techniques | 1 | 2018 | 704 | 0.03 | Why? |
| Peptide Hydrolases | 1 | 2021 | 1269 | 0.03 | Why? |
| Cell Line | 2 | 2019 | 12040 | 0.03 | Why? |
| Ligands | 1 | 2018 | 1300 | 0.03 | Why? |
| Immunophenotyping | 1 | 2018 | 1290 | 0.03 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2020 | 1755 | 0.03 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2017 | 724 | 0.03 | Why? |
| Polymorphism, Restriction Fragment Length | 1 | 2012 | 116 | 0.03 | Why? |
| Gene Expression Regulation, Viral | 1 | 2018 | 925 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.03 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 13720 | 0.03 | Why? |
| Cathepsins | 1 | 2013 | 204 | 0.03 | Why? |
| Transduction, Genetic | 1 | 2013 | 273 | 0.03 | Why? |
| Ventricular Dysfunction, Left | 1 | 2020 | 993 | 0.03 | Why? |
| Switzerland | 1 | 2020 | 2738 | 0.03 | Why? |
| Time Factors | 3 | 2021 | 31397 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| Respiratory Insufficiency | 1 | 2013 | 7301 | 0.03 | Why? |
| Orthomyxoviridae | 1 | 2020 | 1168 | 0.03 | Why? |
| Membrane Fusion | 1 | 2016 | 713 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2021 | 17020 | 0.03 | Why? |
| Pyrimidines | 1 | 2019 | 1557 | 0.03 | Why? |
| Biopsy | 1 | 2020 | 2811 | 0.03 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.03 | Why? |
| Open Reading Frames | 1 | 2018 | 1898 | 0.03 | Why? |
| Leukocytes, Mononuclear | 1 | 2021 | 2115 | 0.03 | Why? |
| Treatment Outcome | 4 | 2020 | 51732 | 0.03 | Why? |
| Virion | 1 | 2019 | 1444 | 0.03 | Why? |
| Antibodies | 1 | 2017 | 846 | 0.03 | Why? |
| Disinfectants | 1 | 2021 | 1077 | 0.03 | Why? |
| Drug Resistance, Viral | 1 | 2017 | 1083 | 0.03 | Why? |
| United Arab Emirates | 1 | 2013 | 704 | 0.03 | Why? |
| CRISPR-Cas Systems | 1 | 2019 | 1397 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Single-Cell Analysis | 1 | 2020 | 2450 | 0.03 | Why? |
| Sequence Homology, Amino Acid | 1 | 2013 | 945 | 0.03 | Why? |
| Reverse Transcription | 1 | 2013 | 673 | 0.03 | Why? |
| Radiography, Thoracic | 2 | 2020 | 5486 | 0.03 | Why? |
| Fluorescent Antibody Technique | 1 | 2012 | 835 | 0.02 | Why? |
| Graft Rejection | 1 | 2020 | 1766 | 0.02 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.02 | Why? |
| Plant Extracts | 1 | 2021 | 1514 | 0.02 | Why? |
| Infant, Newborn | 2 | 2021 | 23105 | 0.02 | Why? |
| Vaccination | 3 | 2021 | 19050 | 0.02 | Why? |
| Pyrazoles | 1 | 2019 | 1791 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2020 | 2654 | 0.02 | Why? |
| China | 3 | 2020 | 50654 | 0.02 | Why? |
| Virology | 1 | 2012 | 489 | 0.02 | Why? |
| Interferons | 1 | 2020 | 2885 | 0.02 | Why? |
| Risk | 1 | 2020 | 5288 | 0.02 | Why? |
| Seasons | 1 | 2020 | 4071 | 0.02 | Why? |
| Infant | 2 | 2021 | 30274 | 0.02 | Why? |
| Proteome | 1 | 2018 | 1812 | 0.02 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.02 | Why? |
| Adjuvants, Immunologic | 1 | 2017 | 1709 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.02 | Why? |
| Phylogeny | 2 | 2018 | 13341 | 0.02 | Why? |
| Interferon-beta | 1 | 2013 | 979 | 0.02 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2019 | 4020 | 0.02 | Why? |
| RNA, Messenger | 1 | 2021 | 5131 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| Child, Preschool | 2 | 2021 | 36283 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2016 | 3786 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.02 | Why? |
| Up-Regulation | 1 | 2013 | 2249 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Viral Tropism | 1 | 2013 | 1329 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Drug Discovery | 1 | 2018 | 3092 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2012 | 2830 | 0.02 | Why? |
| Fatal Outcome | 1 | 2013 | 3438 | 0.02 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2021 | 23402 | 0.02 | Why? |
| Shock, Septic | 1 | 2013 | 1313 | 0.02 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.01 | Why? |
| Saudi Arabia | 1 | 2013 | 4423 | 0.01 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Anti-Infective Agents | 1 | 2013 | 1766 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Lymphocytes | 1 | 2013 | 3056 | 0.01 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Laboratories | 1 | 2012 | 2858 | 0.01 | Why? |
| Feces | 1 | 2013 | 4235 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 11367 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Serine Endopeptidases | 1 | 2013 | 4606 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2021 | 14232 | 0.01 | Why? |
| Prospective Studies | 1 | 2021 | 43301 | 0.01 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.01 | Why? |
| Lung | 1 | 2013 | 31049 | 0.00 | Why? |